It is perhaps unsurprising that GLP-1 therapeutics show greater efficacy compared with traditional diabetic medicines, due to their potential to address not only acute stimulation of insulin secretion in response to a rise in blood glucose, but also slow the progressive loss of β-cell function and tissue mass in T2D. Here, INS is linked to type 2 diabetes mellitus.